Drugs

SENTRY study – investigating the safety and efficacy of the combination of selinexor plus ruxolitinib in myelofibrosis

Photo from Icahn School of Medicine at Mount Sinai/X

Aug 12, 2024, 13:49

SENTRY study – investigating the safety and efficacy of the combination of selinexor plus ruxolitinib in myelofibrosis

Icahn School of Medicine at Mount Sinai shared on X:

“The SENTRY study, led by Dr. John Mascarenhas, is investigating the safety and efficacy of the combination of selinexor (Xpovio) plus ruxolitinib (Jakafi) for the treatment of patients with JAK inhibitor treatment-naive myelofibrosis.”

Read further.
Source: Icahn School of Medicine at Mount Sinai/X

cancer Icahn School of Medicine at Mount Sinai John Mascarenhas myelofibrosis OncoDaily Oncology ruxolitinib (Jakafi) selinexor (Xpovio) SENTRY SENTRY trial

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results

Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer

Funding Impactful Cancer Research That Might Otherwise Go Unsupported: Ryan Schoenfeld on the Secret Behind Mark Foundation’s Success

One Hand Gives, Another Takes? Trump, Musk, Congress and Childhood Cancer Research Funding

Fabrice André has been elected as the President of the ESMO for the term 2025-2026

Special Coverage